Tag: Stereotaxis

Stereotaxis Reports 2023 Full Year Financial Results

ST. LOUIS, March 04, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2023. “We enter 2024 having made significant progress in realizing our strategic […]

Stereotaxis to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024

ST. LOUIS, Feb. 20, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2023 fourth quarter and full year ended December 31, 2023 on Monday, March 4, 2024 at […]

Stereotaxis Announces First Patients Successfully Treated Using MAGiC Ablation Catheter

ST. LOUIS, Jan. 08, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced that the first patients have been successfully treated using its Magnetic Interventional Ablation Catheter, MAGiC™. Stereotaxis’ MAGiC catheter is a robotically navigated magnetic ablation catheter designed to […]

Baptist Health Lexington Enhances 20-Year Leadership in Pioneering Advanced Robotic Technology for Heart Disease Patients

LEXINGTON, Ky. and ST. LOUIS, Nov. 28, 2023 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, and Baptist Health Lexington, a leading health provider in Kentucky, today announced that physicians have built upon their two-decades of leadership in robotic heart care with […]

Abbott and Stereotaxis Technologies Used in First Integrated Procedures in the United States

ST. LOUIS, Oct. 31, 2023 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first patients in the United States have been treated successfully utilizing Abbott’s EnSite™ X EP System integrated with Stereotaxis’ Robotic Magnetic Navigation System. […]

Stereotaxis to Initiate First-in-Human Trial to Support CE Mark Application of MAGiC Catheter

ST. LOUIS, June 15, 2023 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it intends to initiate a first-in-human trial to support the CE Mark submission for its MAGiC™ catheter. Stereotaxis’ MAGiC catheter is a robotically-navigated […]

Stereotaxis and Abbott Announce Global Collaboration Combining Leading Mapping and Robotic Technologies to Improve Treatment of Abnormal Heart Rhythms

ST. LOUIS, May 19, 2023 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS) today announced a global collaboration with Abbott (NYSE: ABT) to integrate Abbott’s EnSite™ X EP System with Stereotaxis’ Robotic Magnetic Navigation systems. The combination of Abbott’s leading cardiac mapping system with Stereotaxis’ advanced robotic technology brings together highly detailed real-time diagnostic information with […]

Broward Health Medical Center the First Hospital in Florida Using Advanced Genesis Robotic Technology to Treat Heart Rhythm Disorders

ST. LOUIS, March 20, 2023 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the grand opening of a new robotic electrophysiology program at Broward Health Medical Center in Fort Lauderdale, Florida. Broward Health is among the first in the […]